ClinicalTrials.gg
CompletedNCT01005966Updated Jul 29, 2013Results posted

In Situ Caries Model of Fluoride Toothpastes

A Phase 3 interventional study of Sodium Fluoride Toothpaste and Amine Fluoride Toothpaste in Caries, sponsored by GlaxoSmithKline. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-29.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is to evaluate the effect of fluoride dentrifrices on enamel with artificial caries lesions in an in situ model

02

Conditions studied

  • Caries

Keywords

  • remineralization
  • enamel
  • in situ
  • fluoride
  • caries
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consent:Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written and has received a signed and dated copy of the informed consent form
  • Age:Aged 18 to 80 years inclusive
  • Compliance: Understands and is willing, able and likely to comply with all study procedures and restrictions
  • General Health:Good general health with (in the opinion of the investigator) no and/or relevant abnormalities of medical history or oral examination that could interfere with subject safety during the study period
  • Residency: Currently living in the Indianapolis, Indiana area
  • Dentures: a) Currently wearing a removable mandibular partial denture with sufficient room in the posterior buccal flange area to accommodate two enamel specimens (required dimensions 12 x 7 millimeters (mm). b) Willing and capable of wearing their removable partial dentures 24 hours per day during each two week treatment period. c) All restorations in a good state of repair
  • Salivary Flow: Have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 mL/minute; gum base stimulated whole saliva flow rate ≥ 0.8 mL/minute).

Exclusion criteria

Exclusion Criteria:

  • Pregnancy:Women who are known to be pregnant or who are intending to become pregnant over the duration of the study
  • Breast-feeding: Women who are breast-feeding
  • Allergy/Intolerance:Known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients
  • Clinical Study/Experimental Medication: a. Participation in another clinical study or receipt of an drug within 30 days of the first treatment visit, with the exception of study GSK dental studies where the wash in period prior to treatment is sufficient. b. Previous participation in this study
  • Antibiotics: Currently taking antibiotics or have taken antibiotics in the two weeks prior to the screening visit
  • Fluoride: Prescribed or professionally recommended use of fluoride supplements or fluoride mouthrinse
  • Substance abuse: Recent history (within last year) of alcohol or other substance abuse
  • Dental Health: Current active caries or periodontal disease that may compromise the study or health of the subjects
  • Personnel: a. A member of the site study staff who is directly working on the project or living in that staff's household. b. An employee of the sponsor c. Any employee of any toothpaste manufacturer or their spouse or family member
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
65 participants (actual)

Study arms

  • Other
    Run in

    Placebo

    Drug: Placebo

  • Experimental
    Sodium Fluoride Toothpaste

    Sodium fluoride toothpaste

    Drug: Sodium Fluoride Toothpaste

  • Active comparator
    Amine Fluoride Toothpaste

    Amine Fluoride

    Drug: Amine Fluoride Toothpaste

  • Other
    675ppmf toothpaste

    Dose response

    Drug: 675 ppmf toothpaste

  • Active comparator
    Sodium monofluorophosphate/sodium fluoride Toothpaste

    Sodium monofluorophosphate/sodium fluoride Toothpaste

    Drug: Sodium monofluorophosphate/Sodium Fluoride Toothpaste

  • Placebo comparator
    0 ppmf toothpaste

    Drug: Placebo

Interventions

  • Test product

  • DrugAmine Fluoride Toothpaste

    Test product

  • DrugSodium monofluorophosphate/Sodium Fluoride Toothpaste

    test product

  • DrugPlacebo

    placebo and washout treatment

  • Drug675 ppmf toothpaste

    dose response

06

What researchers measure

Primary outcomes

  1. Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF)

    SMH recovery test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Difference in percent SMH recovery was calculated by comparing study NaF toothpaste (1426ppmF) with reference AmF toothpaste (1400ppmF).

    Time frame: Baseline to 14 days

Secondary outcomes

  1. Percent SMH Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste (1400ppm F) and Placebo (0ppmF)

    SMH test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Differences in percent SMH recovery due to study and reference toothpastes were calculated.

    Time frame: Baseline to 14 days

  2. Change From Baseline in Enamel Fluoride Uptake Potential

    Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.

    Time frame: Baseline to 14 days

07

Results

Posted Jul 29, 2013

Participant flow

Participants were recruited at the clinical site.

Treatment Period 1 (14 Days)
Participant flow — Treatment Period 1 (14 Days)
MilestoneSodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]Amine Fluoride(AmF) Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started1313131313
Completed1113121313
Not completed20100
Withdrew: Adverse event10000
Withdrew: Protocol violation10100
Washout Period 1 (4 Days)
Participant flow — Washout Period 1 (4 Days)
MilestoneSodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]Amine Fluoride(AmF) Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started1113121313
Completed1113121213
Not completed00010
Withdrew: Withdrawal by subject00010
Treatment Period 2 (14 Days)
Participant flow — Treatment Period 2 (14 Days)
MilestoneSodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]Amine Fluoride(AmF) Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started1313121211
Completed1312101111
Not completed01210
Withdrew: Adverse event01100
Withdrew: Protocol violation00010
Withdrew: Withdrawal by subject00100
Washout Period 2 (4 Days)
Participant flow — Washout Period 2 (4 Days)
MilestoneSodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]Amine Fluoride(AmF) Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started1312101111
Completed1312101111
Not completed00000
Treatment Period 3 (14 Days)
Participant flow — Treatment Period 3 (14 Days)
MilestoneSodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]Amine Fluoride(AmF) Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started128121312
Completed127121311
Not completed01001
Withdrew: Protocol violation01001
Washout Period 3 ( 4 Days)
Participant flow — Washout Period 3 ( 4 Days)
MilestoneSodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]Amine Fluoride(AmF) Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started127121311
Completed127121311
Not completed00000
Treatment Period 4 (14 Days)
Participant flow — Treatment Period 4 (14 Days)
MilestoneSodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]Amine Fluoride(AmF) Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started1011111013
Completed1010111012
Not completed01001
Withdrew: Protocol violation01000
Withdrew: Other reason00001
Washout Period 4 (4 Days)
Participant flow — Washout Period 4 (4 Days)
MilestoneSodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]Amine Fluoride(AmF) Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started1010111012
Completed1010111012
Not completed00000
Treatment Period 5 (14 Days)
Participant flow — Treatment Period 5 (14 Days)
MilestoneSodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]Amine Fluoride(AmF) Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started912111110
Completed912111110
Not completed00000

Outcome measures

PrimaryPercent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF)

SMH recovery test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Difference in percent SMH recovery was calculated by comparing study NaF toothpaste (1426ppmF) with reference AmF toothpaste (1400ppmF).

Time frame:
Baseline to 14 days
Reported as:
Mean · Percentage SMHR
Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF)
Percentage SMHRNaF Toothpaste (1426ppmF)AmF Toothpaste (1400ppmF)
Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF)38.05 ± 2.5241.06 ± 2.53
Statistical analysis
  • NaF Toothpaste (1426ppmF) vs AmF Toothpaste (1400ppmF) · ANOVA · p = 0.2117 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: -3.01 · 95% CI -7.75 to 1.73Statistical tests were 2-sided with a significance level of 0.05.
SecondaryPercent SMH Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste (1400ppm F) and Placebo (0ppmF)

SMH test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Differences in percent SMH recovery due to study and reference toothpastes were calculated.

Time frame:
Baseline to 14 days
Reported as:
Mean · Percentage SMHR
Percent SMH Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste (1400ppm F) and Placebo (0ppmF)
Percentage SMHRNaF Toothpaste (1426ppmF)AmF Toothpaste (1400ppmF)NaMFP/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Percent SMH Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste (1400ppm F) and Placebo (0ppmF)38.05 ± 2.5241.06 ± 2.5333.48 ± 2.4929.08 ± 2.5014.49 ± 2.48
Statistical analysis
  • NaF Toothpaste (1426ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.0002 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 8.96 · 95% CI 4.27 to 13.66Statistical tests were 2-sided with a significance level of 0.05.
  • NaF Toothpaste (1426ppmF) vs NaMFP/NaF Toothpaste (1450ppmF) · ANOVA · p = 0.0557 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 4.57 · 95% CI -0.11 to 9.24Statistical tests were 2-sided with a significance level of 0.05.
  • NaF Toothpaste (1426ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 23.55 · 95% CI 18.86 to 28.24Statistical tests were 2-sided with a significance level of 0.05.
  • NaMFP/NaF Toothpaste (1450ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.0625 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 4.40 · 95% CI -0.23 to 9.03Statistical tests were 2-sided with a significance level of 0.05.
  • NaMFP/NaF Toothpaste (1450ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 18.99 · 95% CI 14.36 to 23.61Statistical tests were 2-sided with a significance level of 0.05.
  • NaF Toothpaste (675ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 14.59 · 95% CI 9.95 to 19.23Statistical tests were 2-sided with a significance level of 0.05.
  • AmF Toothpaste (1400ppmF) vs NaMFP/NaF Toothpaste (1450ppmF) · ANOVA · p = 0.0017 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 7.58 · 95% CI 2.88 to 12.27Statistical tests were 2-sided with a significance level of 0.05.
  • AmF Toothpaste (1400ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 11.97 · 95% CI 7.31 to 16.64Statistical tests were 2-sided with a significance level of 0.05.
  • AmF Toothpaste (1400ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 26.56 · 95% CI 21.88 to 31.24Statistical tests were 2-sided with a significance level of 0.05.
SecondaryChange From Baseline in Enamel Fluoride Uptake Potential

Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.

Time frame:
Baseline to 14 days
Reported as:
Mean · micrograms (μg)* F/centimeters(cm)^2
Change From Baseline in Enamel Fluoride Uptake Potential
micrograms (μg)* F/centimeters(cm)^2NaF Toothpaste (1426ppmF)AmF Toothpaste (1400ppmF)Na MFP/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Change From Baseline in Enamel Fluoride Uptake Potential2342.35 ± 123.652305.11 ± 123.831809.74 ± 121.831649.44 ± 121.93462.95 ± 120.92
Statistical analysis
  • NaF Toothpaste (1426ppmF) vs AmF Toothpaste (1400ppmF) · ANOVA · p = 0.7912 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 37.24 · 95% CI -239.62 to 314.09Statistical tests were 2-sided with a significance level of 0.05.
  • NaF Toothpaste (1426ppmF) vs Na MFP/NaF Toothpaste (1450ppmF) · ANOVA · p = 0.0002 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 532.61 · 95% CI 259.06 to 806.16Statistical tests were 2-sided with a significance level of 0.05.
  • NaF Toothpaste (1426ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 692.91 · 95% CI 418.73 to 967.09Statistical tests were 2-sided with a significance level of 0.05
  • NaF Toothpaste (1426ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 1879.40 · 95% CI 1605.75 to 2153.04Statistical tests were 2-sided with a significance level of 0.05.
  • AmF Toothpaste (1400ppmF) vs Na MFP/NaF Toothpaste (1450ppmF) · ANOVA · p = 0.0005 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 495.38 · 95% CI 221.09 to 769.66Statistical tests were 2-sided with a significance level of 0.05.
  • AmF Toothpaste (1400ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 655.67 · 95% CI 382.41 to 928.93Statistical tests were 2-sided with a significance level of 0.05.
  • AmF Toothpaste (1400ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 1842.16 · 95% CI 1568.73 to 2115.60Statistical tests were 2-sided with a significance level of 0.05.
  • Na MFP/NaF Toothpaste (1450ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.2448 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 160.30 · 95% CI -110.58 to 431.18Statistical tests were 2-sided with a significance level of 0.05.
  • Na MFP/NaF Toothpaste (1450ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 1346.79 · 95% CI 1076.46 to 1617.11Statistical tests were 2-sided with a significance level of 0.05.
  • NaF Toothpaste (675ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 1186.49 · 95% CI 915.38 to 1457.60Statistical tests were 2-sided with a significance level of 0.05.

Adverse events

Collected over All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NaF Toothpaste (1426ppmF)—0/57 (0%)1/57 (1.8%)
AmF Toothpaste (1400ppmF)—0/57 (0%)5/57 (8.8%)
NaMFP/ NaF Toothpaste (1450ppmF)—0/59 (0%)0/59 (0%)
NaF Toothpaste (675ppmF)—0/59 (0%)3/59 (5.1%)
Placebo Toothpaste (0ppmF)—0/59 (0%)2/59 (3.4%)
Overall—0/65 (0%)10/65 (15.4%)
Most frequent other events
Most frequent other events
EventNaF Toothpaste (1426ppmF)AmF Toothpaste (1400ppmF)NaMFP/ NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)Overall
NasopharyngitisInfections and infestations1/575/570/593/592/5910/65

Baseline characteristics

Age Continuous
Age Continuous(years)All Randomized Participants
Mean67.0 ± 9.97
Sex: Female, Male
Sex: Female, Male(Participants)All Randomized Participants
Female41
Male24
Region of Enrollment
Region of Enrollment(participants)All Randomized Participants
United States65
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 4 years 4 months after primary completion. A results delay was requested in Nov 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2009
First posted
Nov 1, 2009
Start
Nov 2008
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results delay requested
Nov 28, 2012
Results first posted
Jul 29, 2013
Last update
Jul 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01005966
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 1, 2009
Start date
Nov 2008
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Jul 29, 2013
Last update
Jul 29, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Fluoride

Start the discussion